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The cyclin-like protein Spy1/RINGO promotes
mammary transformation and is elevated in
human breast cancer
Mohammad Al Sorkhy1†, Rosa-Maria Ferraiuolo2†, Espanta Jalili2, Agnes Malysa2, Andreea R Fratiloiu3,
Bonnie F Sloane4 and Lisa A Porter2*
Abstract
Background: Spy1 is a novel ‘cyclin-like’ activator of the G1/S transition capable of enhancing cell proliferation as
well as inhibiting apoptosis. Spy1 protein levels are tightly regulated during normal mammary development and
forced overexpression in mammary mouse models accelerates mammary tumorigenesis.
Methods: Using human tissue samples, cell culture models and in vivo analysis we study the implications of Spy1
as a mediator of mammary transformation and breast cancer proliferation.
Results: We demonstrate that this protein can facilitate transformation in a manner dependent upon the activation
of the G2/M Cdk, Cdk1, and the subsequent inhibition of the anti-apoptotic regulator FOXO1. Importantly, we
show for the first time that enhanced levels of Spy1 protein are found in a large number of human breast cancers
and that knockdown of Spy1 impairs breast cancer cell proliferation.
Conclusions: Collectively, this work supports that Spy1 is a unique activator of Cdk1 in breast cancer cells and may
represent a valuable drug target and/or a prognostic marker for subsets of breast cancers.
Background
The Speedy/RINGO family of proteins are novel regula-
tors of the cell cycle, capable of activating the cyclin-
dependent kinases (Cdks) independent of cyclin binding
and phosphorylation within the Cdk T-loop [1]. The
human Speedy/RINGO homolog, herein referred to as
Spy1, is constitutively expressed in most human tissues
and is essential for somatic cell cycle progression [2].
Ectopic expression of Spy1 promotes rapid cell cycle pro-
gression through G1/S phase that is attributed, at least in
part, to the activation of Cdk2 [2]. Spy1 can prevent the
inhibitory effects of the tumor suppressor p27Kip1 on
Cdk2 by directly promoting p27 degradation, suggesting
yet another mechanism by which Spy1 can enhance both
normal and aberrant cell growth [3-5]. SAGE analysis has
shown that Spy1 is expressed at elevated levels in one
case of invasive ductal carcinoma of the breast [6]. Spy1
protein levels have also been implicated as a prognostic
marker in hepatic carcinogenesis and ectopic overexpres-
sion of Spy1 can accelerate mammary tumorigenesis in
vivo [6-8]. Of potential importance, two independent
linkage studies have resolved that the chromosomal loci
at the precise location of Spy1 (2p23.2) may be a candi-
date site contributing toward breast cancer risk, particu-
larly in women under the age of 50 [9,10]. Hence, how
Spy1 levels contribute to the initiation and/or progres-
sion of tumorigenesis is of high priority for understand-
ing both normal and abnormal cell growth programs.
Spy1 protein levels are tightly regulated during the cell
cycle, being transcriptionally upregulated by the onco-
gene c-Myc [8,11,12]. We have resolved three residues
within the N-terminal region of the protein; T15, S22,
and T33 which are essential for targeting Spy1 for ubi-
quitin-mediated degradation in G2/M phase of the cell
cycle [11]. Mutation of these residues generates a non-
degradable form of Spy1 (Spy1-TST) which significantly
enhances cell proliferation over that of wild-type Spy1
[11]. Herein, we demonstrate that: (1) elevated levels of
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Spy1 is a transforming event, (2) Spy1-mediated transfor-
mation relies on the activation of Cdk1 and may mediate
an inhibition of the pro-apoptotic regulator FOXO1, (3)
levels of Spy1 protein are highly elevated in aggressive
human breast cancers and (4) downregulation of Spy1
can significantly inhibit breast cancer cell growth. Collec-
tively these data support that Cdk1 kinase activity is
essential for Spy1-mediated transformation and may indi-
cate a therapeutically relevant mechanism of treating
tumors with elevated levels of Spy1 protein.
Methods
Cell Culture
The mouse embryonic fibroblast cell line NIH3T3
(ATCC), human embryonic kidney cell line HEK-293
(293; ATCC) and human breast cancer line MDA-MB-
231 (MDA-231; ATCC) were maintained in DMEM
medium (Sigma) supplemented with 10% (vol/vol) calf
serum (Sigma) for NIH3T3 cells, and fetal bovine serum
(FBS; Sigma) for 293 cells. The BALB/c mouse mammary
epithelial cell line HC11 (Dr. C. Shermanko) and breast
cancer MCF7 cells (Dr. T. Seagroves) were maintained in
RPMI 1640 medium (Sigma) containing 10% (vol/vol)
fetal calf serum and supplemented with 5 μg/ml insulin
(Sigma), and 10 ng/ml EGF (Gibco). Human breast
MCF10A series cell lines (ATCC & Drs. B. Sloane and F.
Miller) were maintained in DMEM-F12 media containing
0.5 ug/ml hydrocortisone, 10 ug/ml insulin, 20 ng/ml
human EGF and 5% (vol/vol) horse serum heat inacti-
vated. The MMTV-Myc cell line was derived from a
freshly dissected mammary adenocarcinoma from a 3
month multiparous MMTV-Myc female mouse. All cell
lines were maintained in a media containing 2 mM
L-glutamine (G7513; Sigma), penicillin and streptomycin
(15140; GIBCO), and were cultured in a 5% CO2 environ-
ment. Cells not received from ATCC were tested for
tissue/species specific genes and characteristic receptor
status via Q-RT-PCR. These tests, as well as testing for
mycoplasma, bacteria, fungi contamination and cytoge-
netic characterization are performed on cells obtained
from ATCC.
Plasmid and mutagenesis
Creation of the Myc-Spy1-PCS3 vector was described pre-
viously [13]. Spy1-TST was created using QuickChange
PCR Multi-Site-Directed Mutagenesis (Stratagene) of
Spy1-PCS3 in 3 sequential steps to generate alanine muta-
tions at positions T15, S22 and T33. Successful cloning
was determined by DNA sequencing (Robarts Sequencing
Facility; UWO). Plasmids for FLAG-FOXO1 (#9036), HA-
Cdk1 (#1888), HA-Cdk1-DN (#1889), pLKO-scrambled
control (#8453), the luciferase reporter construct 3xIRS
(#13511) and lentiviral constructs: pMD.G (#12259),
pMDLg/pRE (#12251) and pRSV-Rev (#12253) were all
obtained from Addgene. pLKO Spy1 was cloned to
express the short hairpin previously demonstrated to spe-
cifically knockdown Spy1 in place of the scrambled
sequence in pLKO above [2]. pSUPER (Oligoengine) con-
taining a scrambled siRNA and pSUPER with siSpy1 are
previously described [11]. Generous gifts; FOXO1-A3/
S249A (Dr. H. Huang; University of Minnesota), luciferase
control plasmids (Dr. B. Vogelstein; Johns Hopkins Uni-
versity) and Ras-V12 (Dr. S. Lowe; Cold Spring Harbor).
Antibodies
Primary antibodies were as follows: Spy1 (NB100-2521;
Novus), Myc (9E10 and C19; Santa Cruz), HA (Y11 and
F7; Santa Cruz), Cdk1 (ab31687; Abcam), TOTO-3 (T-
3600; Molecular Probes), IgG (SC66186; Santa Cruz),
Cdk2 (SC-6428; Santa Cruz), Flag (F3040; Sigma) and
actin (MAB1501R; Chemicon).
Transfection/infection methods
Cells were transfected using polyethylenimine (PEI)
branched reagent (408727; Sigma). In brief, for experi-
ments using a fixed amount of DNA per construct 10 μg
of DNA was mixed with 50 μL of 150 mM NaCl and 3 μL
of 10 mg/ml PEI for 10 min then added to a 10 cm tissue
culture plate. For transfections requiring more DNA as
specified, the relative amounts of NaCl and PEI were
scaled up accordingly. Media was changed after 8 h for
NIH3T3s and MCF7s and remained overnight for the 293
cells. For viral preparation: media was changed after 8 h
transfection of packaging lines and virus harvested 24 h
later. Virus was sterilized using a 0.45 μm filter and con-
centrated using ultracentrifugation for 3 h at 25 K rpm at
4°C. Viral titre was determined using HC11 cells. Using a
titre of 107/ml and an MOI of 10, MDA-231 cells were
infected ~70-80% confluency in serum free and antibiotic
free media containing polybrene (25 μg/mL). Media was
replaced 6 h post-infection. Proliferation assays were con-
ducted by counting live and dead cell populations using
trypan blue exclusion and using a haemocytometer; counts
were also verified using a TC10 automated cell counter
(Biorad).
Cell synchronization and flow cytometry
Cells were synchronized using double thymidine block;
cells were cultured in a media containing 2 mM thymidine
for 16 h, released to normal media for 8 h, followed by a
14 h block in 2 mM thymidine and then released in 70 ng
nocodazole. NIH3T3 cells were synchronized by being cul-
tured in a 2% serum containing media for 24 h, followed
by release in standard culture media.
Flow cytometry analysis; cells were carefully collected
at indicated times (taking care to include even floating
cell populations), washed twice in PBS, and then either
used immediately or fixed for future analysis. Fixed cells
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were resuspended at 2 × 106 cells in 1 ml of PBS, fixed
by the dropwise addition of an equal amount of ethanol,
and frozen at -80°C. Within 1 week, fixed cells were pel-
leted, washed, and resuspended in 300 μl of PBS. Sam-
ples of resuspended fixed cells or fresh cells were
treated with 1 μl of 10 mg/ml stock of DNase free
RNase (Sigma) and 50 μl of 500 mg/ml propidium
iodide solution. Cells shown were first gated for size
using forward scatter and side scatter parameters. A
minimum of 300,000 cells were analyzed per treatment
using a Beckman Coulter FC500.
Immunoblotting (IB) and immunoprecipitation (IP)
Cells were lysed in 0.1% NP-40 lysis buffer (5 ml 10% NP-
40, 10 ml 1 M Tris pH 7.5, 5 ml 0.5 M EDTA, 10 ml 5 M
NaCl up to 500 ml RO water) containing protease inhibi-
tors (10 μg/ml PMSF, 60 μg/ml aprotinin, 10 μg/ml leu-
peptin) for 30 min on ice. Bradford Reagent was used to
determine the protein concentration (Sigma). 20-30 μg
protein were subjected to electrophoresis on denaturing
SDS polyacrylamide gels and transferred to PVDF-Plus
0.45U transfer membranes (Osmonics Inc.) for 2 h at 30 V
using a wet transfer method. Blots were blocked for 2 h in
TBST containing 3% non-fat dry milk (blocker) at RT, pri-
mary antibodies were reconstituted in blocker and incu-
bated overnight at 4°C, secondary antibodies were used at
a 1:10,000 dilution in blocker for 1 h at RT. Blots were
washed three times with TBST following incubation with
both the primary and secondary antibodies. Washes were
6 min each following the primary antibody and 10 min
each following the secondary antibody. Blots were visua-
lized using Chemilumiminescent Peroxidase Substrate
(Pierce) and quantified on an Alpha Innotech HD2
(Fisher) using AlphaEase FC software.
For IP, equal amounts of protein were incubated with
primary antisera as indicated overnight at 4°C, followed
by the addition of 10 ul protein A-Sepharose (Sigma) and
incubated at 4°C with gentle rotation for an additional
2 h. These complexes were then washed 3× with 0.1%
NP-40 lysis buffer and resolved by 10% SDS-PAGE.
Tissue microarray (TMA) analysis
Paraffin embedded TMA slides (cat # BR721 and BR962;
US Biomax) consisting of 165 tissue cores in total were
deparaffinized and rehydrated in decreasing percentages of
ethanol according to the manufacturer’s instructions.
Antigen retrieval was performed at 95°C in 0.01 M sodium
citrate buffer, pH 6.0. Slides were washed in 1× PBS, per-
meabilized in 1 × PBS/0.2% Triton X-100 at RT followed
by 3 washes with 1 × PBS. Sections were blocked in goat
serum for 1 h at 37’C, followed by incubation in primary
antibody for 2 h at 37°C. Slides were washed twice for 10
min in PBS-1% normal goat serum. Secondary antibodies
were applied for 1 h at 37°C, washed 3× for 10 min each
in 1 × PBS and incubated 30 min with a nuclear counter-
stain for TOTO-3. The fluorescent signal was detected
and quantified by ScanArray Express (Perkin Elmer Inc.).
The Spy1 signal intensity was normalized to nuclear stain
signal.
Soft agar assay
Two layers of agar/media mixture were plated into 60 mm
culture dishes. Briefly, 0.6 g of Noble agar (UBS) was sus-
pended in 100 ml DI water to yield a 0.6% bottom agar
solution. This mixture was poured into two 50 ml tubes,
sealed and placed at 40°C for 40 min. Simultaneously;
DMEM media enriched with 20% FBS was also incubated
at 40°C. The bottom agar layer contained 1.5 ml of 0.6%
agar solution and 1.5 ml of media solution was poured
and plated. When solidified, a top agar layer was prepared
containing a 3% agar solution. Cells (~2.5 × 105) were har-
vested, counted and added to the top agar + media mix
and then promptly layered onto the bottom agar layer.
Plates were set for 1 h under sterile conditions and then
incubated at 37°C in 5% CO2 for 12-14 days. Triplicate
transfections for each experiment were observed using
light microscopy and pictures were taken using an Apha
Innotech HD2 camera. Colonies were counted manually
using light microscopy.
Focus assay
Low passage cells were grown in 10 cm plates, trans-
fected as above and grown to confluence. Media with
2% calf serum was gently changed every other day for
up to two weeks. Plates were stained with 0.5% crystal
violet, photographed using an Apha Innotech HD2 cam-
era and the number of colonies were counted manually.
Fat pad transplants
Mice were maintained following the guidelines of the
Canadian Council on Animal Care under the ethical
approval of the Animal Care Committee, University of
Windsor (AUPP #06-19). Fat pad transplant assays were
conducted using BALB/c mice, which are syngenic for the
HC11 cell line as previously described [8]. In brief, 5 × 105
cells were injected into the cleared fat pad of 4th inguinal
mammary glands of 22 day old mice and allowed to grow
for 1 to 8 week. Tumor presence was monitored weekly by
palpitation of the gland. Animals were sacrificed humanely
at the specified time points and glands dissected for analy-
sis. Tumor volume was calculated as length (mm) × width
(mm) × height (mm) using manual calipers.
Kinase assays
Cells were transfected, cultured in 10% FBS and lysed in
0.1% NP-40 lysis buffer. 16 h post-transfection IP was
carried out as described above and precipitates were
washed four times prior to the addition of 50 μl of
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kinase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2,
1 mM DTT, 20 mM EGTA, 50 mM ATP, 10 μCi of
[g-32P]ATP) and 74 μg/ml H1 histone (Boehringer Man-
nheim). Reactions were incubated for 10 min at 30°C,
sample buffer was added to stop the reaction and 50 μl
of each sample were analyzed by 10% SDS-PAGE. Incor-
porated phosphorylation was visualized using a Cyclone
storage phosphor system and quantified using Opti-
Quant software (Perkin Elmer). IPs were subsequently
probed on the same membrane.
Luciferase assay
Cells were transfected with the appropriate luciferase
reporter construct, harvested 24 h post-transfection and
50 ul of cell suspension was mixed with 50 ul of Bright-
glo reagent (E2620; Promega). Luminescence spectra of
the samples were measured using a plate reader (Wallac
Victor 1420).
Statistical analysis
Results are presented as the mean ± standard error. Statis-
tical significance was assessed through either a student’s
t-test (analysis of two means) or analysis of variance
(ANOVA) followed by a post-hoc Tukey test (for more
than two means with equal variances) or post-hoc Bonfer-
roni (for more than two means without equal variances).
StatSoft’s STATISTICA software was used for all analysis.
Results and Discussion
Spy1 is an essential cell cycle regulator capable of enhan-
cing cell growth and inhibiting apoptosis [2,14]. Spy1 has
been implicated as a prognostic marker in hepatocarci-
noma, and increased levels accelerate mammary tumour
formation in mouse models [7,8]. To further determine
whether accumulating levels of Spy1 protein represent a
transforming and potentially oncogenic event, HEK 293
cells were transfected with increasing amounts of Spy1-
WT or Spy1 with a modified N-terminal degradation sig-
nal (Spy1-TST) and soft agar assays were performed.
Enhancing or stabilizing Spy1 protein levels resulted in a
concentration dependent increase in colony formation
(Figure 1A). It was noted that while protein levels and sub-
sequent colony formation increased proportionately with
the amount of cDNA transfected, colony formation was
not simply a reflection of total amount of Spy1 protein
(Figure 1A & B). Using approximately half the amount of
transfected DNA for Spy1-TST resulted in a statistically
significant reduction of overall protein levels of ~30%, but
at least a 2-fold increase in colony formation with high
statistical significance (compare 30 ug Spy1-WT vs. 15 ug
Spy1-TST). This suggests the possibility that threshold
levels or stabilization of the Spy1 protein triggers a unique
mechanism that may contribute toward Spy1-mediated
tumorigenesis. The significant increase in colonies seen
with the Spy1-TST mutant over Spy1-WT supports that
the G2/M degradation mechanism previously described
[11] may provide a protective barrier against this poten-
tially oncogenic pathway.
To test this hypothesis, soft agar assays were conducted
using similar protein levels of either Spy1-WT or Spy1-
TST, along with activated Ras (Ras-V12) as a positive con-
trol and empty pCS3 as a negative control (Figure 1C).
Colonies were formed in the presence of Ras-V12 as well
as Spy1-TST, but no colonies were present in the negative
control and few colonies were detected for Spy1-WT (Fig-
ure 1C). Quantification over three separate experiments
demonstrated that Spy1-TST yielded 4 times more colo-
nies than the Spy1-WT counterpart (Figure 1D). Densito-
metry analysis of protein levels of transfected Spy1 at the
time of seeding, normalized using Actin levels, show less
than a 2 fold increase in the overall Spy1 protein levels
with Spy1-TST (Figure 1E). The modest increase in pro-
tein accumulation with Spy1-TST is not surprising given
that we are utilizing asynchronous cells and there are mul-
tiple mechanisms for regulating Spy1 protein levels
[11,12]. Functionally, this supports that the transforming
properties of Spy1-TST are not explained merely by the
accumulation of overall amounts of protein.
To further test this result on the parameters of con-
tact inhibition we performed a foci formation assay
using the NIH3T3 cell line (Figure 2A). A significantly
higher number of foci were formed from the Spy1-TST
and Ras-V12 expressing cells as compared to Spy1-WT
counterparts, negligible foci were formed in the control
transfected cells (Figure 2B). Modest difference in rela-
tive protein levels (Figure 2B, right panel) further sup-
port, as above, that Spy1-TST effects on cell growth
properties are not adequately explained by increases in
overall protein levels.
Spy1 significantly accelerates tumor formation when
HC11 cells overexpressing Spy1 were injected into
cleared fat pad of BALB/c mice [8]. Mammary fat pad
transplants were performed to determine the effect and
timing of Spy1-TST in vivo as compared to similar
protein levels of the overexpression of Spy1-WT (Fig-
ure 3A-B). The fourth inguinal mammary glands of 22
day old BALB/c were cleared and the left fat pad
injected with control Spy1-WT-HC11, whereas the
right fat pad were injected with Spy1-TST-HC11 cells.
One week following transplantation, mice were pal-
pated daily to determine the onset of tumor growth.
Tumor onset occurred more rapidly in the Spy1-TST
injected glands, with 50% of the mice presenting with
tumors by day 8 as compared to day 13 in the Spy1-
WT mouse population (Figure 3A). This was statisti-
cally significant as assessed by the Mann-Whitney
(shown) as well as by Chi-square (p = 0.0003) and the
non-parametric Wilcoxin test (p = 0.008). After 5
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Figure 1 Spy1 stable protein induces anchorage independent growth. (A) 293 cells were transfected with different concentrations of Myc-
Spy1-WT, Myc-Spy1-TST or 30 μg of empty PCS3 vector control. Soft agar assay was carried out and plates photographed and quantified on day
14. Foci were averaged over 3 separate transfections for each experiment. n = 3 (B) Western blot analysis of one representative experiment;
densitometry in lower panel. n = 3 (C) Representative foci after 14 day soft agar assay visualized using light microscopy. Ras-V12 is transfected as
a positive control. n = 3. (D) Total numbers of foci were counted over 3 separate plates using separate transfections for each experiment. n = 3.
Error bars reflect SE between triplicate experiments. t test was performed;** P ≤ 0.01. (E) Western blot analysis of experiments in Figure. 1C & D.
Quantified using densitometry followed by normalization for Actin levels. (A-E) Error bars reflect SE between triplicate experiments. t test was
performed;* P≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
Al Sorkhy et al. BMC Cancer 2012, 12:45
http://www.biomedcentral.com/1471-2407/12/45
Page 5 of 14
weeks post-transplantation, mice were sacrificed to
determine the extensiveness of tumor growth. While
100% of the glands exhibited invasive tumors at this
time, the average total volume of Spy1-TST tumors
was found to be almost twice that of the Spy1-WT
(Figure 3B). The marked increase in transformation
efficiency in vitro and the subtle, albeit significant,
effects on tumour growth in vivo of the TST-Spy1
mutant support that overriding the degradation of Spy1
during G2/M may result in the activation of unique
Figure 2 Elevated Spy1 levels prevent contact inhibition. (A) Representative views of focus formation assays in NIH3T3 cells transfected with
Myc-Spy1-WT, Myc-Spy1-TST, positive control Ras-V12 or empty vector PCS3 control. n = 3 (B) Quantification of the number of colonies. Error
bars reflect SE between triplicate experiments. t test was performed;** P ≤ 0.01. n = 3 (right panel) Western blot analysis of one representative
lysate from A-B.
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pathways that contribute toward Spy1-mediated tumor-
igenesis. The ultimate formation of tumors in 100% of
animals with Spy1-WT (Figure 3A), and the fact that
tumour volume differences are most significant at the
earliest time points post-surgery (Figure 3B; right
panel), support that, as seen in Figure 1A, threshold
levels of Spy1 protein may also contribute toward this
tumorigenic mechanism.
Spy1 protein is known to regulate cell cycle progression
at least in part through the direct binding to Cdks [2]. In
somatic cells the primary partner for Spy1, and an essen-
tial regulator of Spy1-mediated proliferation, appears to
be the G1/S Cdk, Cdk2 [2]. Spy1 is capable of also bind-
ing and activating Cdk1 when overexpressed [15]. To
determine the role of Cdk proteins on Spy1-mediated
transformation we utilized a mutant form of Spy1-TST
Figure 3 Spy1 stable protein accelerates tumorigenesis in vivo.(A) Percentage of mice presenting with palpable tumors from 0-19 days
post-transplant. Each data point represents 4 mice per indicated construct. The entire experiment was repeated three times using three
independently derived overexpressing cell lines for each construct. Mann-Whitney Test was performed (p < 0.05). (A; lower blot) Western blots
were conducted to measure the stability of Myc-Spy1-WT (left) and Myc-Spy1-TST (right) from representative time points. Empty vector control
(Cntl) cell expression levels of Spy1 are seen in lane 1 of each blot. (B) Total tumor volume was calculated for both Spy1-HC11 (Spy1-WT) and
Spy1-TST-HC11 (Spy1-TST) transplanted glands. Results were taken from 45 transplants using cells from 3 separate transfections. Error bars reflect
SE between transplants from different transfections. Left hand panel reflects overall volume, right hand panel reflects volumes of tissues taken
over a month post-transplant.
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where the aspartic acid residue at position 90 is mutated
to a nonpolar alanine group (Spy1-TST/D90A), a modifi-
cation previously demonstrated to significantly reduce
Spy1-Cdk binding [15]. We demonstrate that this muta-
tion also abrogates the ability of Spy1-TST to interact
with Cdk1 (Figure 4A). The Spy1-TST/D90A mutation
reduced colony formation in soft agar approximately 5-
fold compared to Spy1-TST (Figure 4B & C). To further
investigate the relative contribution of each kinase indivi-
dually to this effect, soft agar assays were performed
using Spy1-TST in the presence of the dominant negative
form of either Cdk1 (Cdk1-DN) or Cdk2 (Cdk2-DN)
(Figure 4D). Interestingly, Cdk1-DN reduced colony for-
mation by ~60% with high statistical significance over 3
separate trials while Cdk2-DN demonstrated reduced
colony numbers but this result was not statistically
Figure 4 Spy1 mediated colony formation is Cdk1 dependent . 293 cells transfected with the indicated constructs were (A)
immunoprecipitated for HA tagged-Cdk1 and blotted for Myc and HA tag. n = 3 (B) imaged after 14 days in a soft agar assay. Transfections and
protein levels were monitored by western blot analysis (inset). n = 3 (C) Quantification of colony number over three separate transfections. (D)
Soft agar assays of cells transfected in triplicate with Myc-Spy1-TST in the presence or absence of Cdk dominant negative constructs (Cdk1-DN or
Cdk2-DN). n = 3 Plates are imaged and quantified at day 14. Errors bars reflect SD between triplicate experiments. ANOVA with post hoc analysis
using Tukey test was performed;* P ≤ 0.05, ** P ≤ 0.01.
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significant. This was not due to inefficient function of the
constructs as both DN constructs effectively reduced the
kinase activity of their relevant Cdk (Additional file 1:
Figure S1). Collectively this data supports that the onco-
genic function of Spy1 is dependent, at least in part, on
the binding and activation of Cdk1.
Spy1 protein is known to regulate cell cycle progression
at least in part through the direct binding to Cdks [2]. In
somatic cells the primary partner for Spy1, and an essen-
tial regulator of Spy1-mediated proliferation, appears to
be the G1/S Cdk, Cdk2 [2]. Spy1 is capable of also bind-
ing and activating Cdk1 when overexpressed [15]. To
determine the role of Cdk proteins on Spy1-mediated
transformation we utilized a mutant form of Spy1-TST
where the aspartic acid residue at position 90 is mutated
to a nonpolar alanine group (Spy1-TST/D90A), a modifi-
cation previously demonstrated to significantly reduce
Spy1-Cdk binding [15]. We demonstrate that this muta-
tion also abrogates the ability of Spy1-TST to interact
with Cdk1 (Figure 4A). The Spy1-TST/D90A mutation
reduced colony formation in soft agar approximately 5-
fold compared to Spy1-TST (Figure 4B & C). To further
investigate the relative contribution of each kinase indivi-
dually to this effect, soft agar assays were performed
using Spy1-TST in the presence of the dominant negative
form of either Cdk1 (Cdk1-DN) or Cdk2 (Cdk2-DN)
(Figure 4D). Interestingly, Cdk1-DN reduced colony for-
mation by ~60% with high statistical significance over 3
separate trials while Cdk2-DN demonstrated reduced
colony numbers but this result was not statistically signif-
icant. This was not due to inefficient function of the con-
structs as both DN constructs effectively reduced the
kinase activity of their relevant Cdk (Additional file 1:
Figure S1). Collectively this data supports that the onco-
genic function of Spy1 is dependent, at least in part, on
the binding and activation of Cdk1.
We previously demonstrated that Spy1-TST remains
stabilized at pro-metaphase of mitosis when microtubule
polymerization was prevented using nocodazole treat-
ment; a time point where Spy1-WT was completely
degraded [11,12]. Hence, we sought to determine
whether aberrant degradation of Spy1 will result in ele-
vated Cdk1 activity during mitosis. Cdk1 has been shown
to play an important role in different human cancers,
aberrant Cdk1 activation has been described in number
of primary tumors [16], providing a potential novel
mechanism for Spy1- mediated oncogenic effects. Reci-
procal immunoprecipitation of exogenously expressed
Spy1-TST (Figure 5A; left panels) or Cdk1 (right panels)
demonstrate that these proteins interact in cells blocked
with nocodazole. We also demonstrate this interaction
using endogenous Cdk1 (Figure 5B). To further investi-
gate if Spy1-TST expression leads to unique activation of
Cdk1, cells overexpressing Spy1-WT or Spy1-TST were
synchronized in prometaphase followed by immunopre-
cipitation with Cdk1 antibody and subject to an in vitro
kinase assay (Figure 5C). Spy1-TST significantly
increased substrate (histone) phosphorylation demon-
strating approximately a 3-fold increase over control
transfected cells and approximately a 2-fold increase over
Spy1-WT transfected cells (Figure 5C). Control trans-
fected cells were collected prior to synchronization to
ensure that both Spy1-WT and Spy1-TST were trans-
fected (Figure 5B; right panels). Several reports have
shown that aberrant activation and/or elevated levels of
Cdk1 or upstream activators are implicated in several
forms of human cancer [17-20]. Spy1 binding to its rela-
tive Cdk partners has demonstrated unique substrate
specificity [21], offering the possibility that Spy1 binding
to Cdk1 is uniquely required to promote the oncogenic
properties of Cdk1.
Huang and colleagues reported that Cdk1 activation
inhibits the transcriptional and apoptotic activities of the
transcription factor FOXO1, thereby potentiating Ras-
mediated oncogenesis [22]. To investigate the effect of
Spy1 on FOXO1-induced apoptosis, HEK-293 cells were
transfected with FOXO1 in the presence or absence of
Spy1-WT or Spy1-TST and/or variants of Cdk1 (Figure
6A-D). Double transfection with FOXO1 and Spy1-WT
resulted in significant reduction of a sub-G1 population
of cells induced by FOXO1 (Figure 6A). To test if this
reduction was mediated through Cdk1 activation, a
Cdk1-DN was transfected along with Spy1-WT and
FOXO1 (Figure 6A). The effect of Spy1-WT was indeed
reversed by the introduction of the Cdk1-DN, supporting
that Spy1 inhibition of apoptosis is due to Cdk1 activa-
tion. To further investigate the effect of Spy1 on FOXO1
transcriptional activity, a series of luciferase assays were
performed (Figure 6B-D). Ectopic expression of Spy1-
TST reduced FOXO1 transcriptional activity as signifi-
cant as the expression of Cdk1 (Figure 6B). It has been
demonstrated that Cdk1 phosphorylates FOXO1 on S249,
a modification that inhibits FOXO1 transcriptional activ-
ity [22,23]. Hence, to determine if Spy1-Cdk1 also func-
tions through this site we utilized a mutant of FOXO1
unable to be phosphorylated by Cdk1; FOXO1-S249A
(Figure 6C) [22,23]. Ectopic transfection of Spy1-TST
with FOXO1-S249A prevented the inhibition of FOXO1
transcription by Cdk1 and by Spy1-TST. Furthermore,
Spy1-TST was unable to suppress FOXO1-mediated tran-
scription in the presence of Cdk1-DN (Figure 6D). These
results support that Spy1 is capable of inhibiting FOXO1-
mediated transcription through the activation of Cdk1.
Spy1 protein levels are elevated in human hepatocarci-
noma and overexpression of Spy1 protein promotes
tumorigenesis in mouse models; however, whether Spy1
protein levels are implicated in human breast cancer has
not been previously demonstrated [6,7]. TMAs containing
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Figure 5 Spy1 stable protein binds and activates Cdk1.(A) 293 cells transfected with HA-Cdk1 and Myc-Spy1-TST were treated with 70 ng
Nocodazole for 16 h followed by IP for either Myc or HA. IP with IgG was used as a negative control. Top panels indicate IPs and bottom
panels represent the lysate loading controls. n = 2 (B) 293 cells transfected with the indicated constructs were IPd for Spy1 using the Myc tag
and analyzed by 10% SDS-PAGE/IB. n = 3 (C) 293 cells transfected with the indicated constructs were treated with 70 ng nocodazole for 16 h.
Cdk1 IPs were subject to a H1 phosphorylation assay followed by 10% SDS-PAGE. Membranes were imaged on a Cyclone phosphorimager then
probed with Cdk1 and imaged on an Alpha Innotech HD2. n = 3 Errors bars reflect SE. t test was performed *P < 0.05;**P < 0.01.
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a total of 165 cores of the most prevalent forms of breast
cancer were used to determine whether levels of Spy1 pro-
tein are indeed implicated in human breast cancer. Spy1
antibody specificity was previously published [11] and is
further confirmed in Figures 7B and 7C. This data demon-
strates that Spy1 is significantly elevated in all forms of
breast cancer tested over pair-matched adjacent or normal
tissue (Figure 7A). Protein levels of Spy1 were highest in
invasive lobular carcinoma and the most significant
changes in levels were found in intraductal carcinoma.
These data were quantified digitally (Figure 7A) and were
confirmed via manual imaging of the TMA slides (Addi-
tional file 2: Figure S2B). Spy1 levels have been demon-
strated to be high in all proliferative normal mammary
tissue [8], we ran a number of breast cancer lines together
to select the lines expressing the highest level of Spy1 pro-
tein for functional analysis (Figure 7B). Spy1 protein levels
were found to be at particularly high levels in the
Figure 6 Spy1 inhibits FOXO1 induced apoptosis through Cdk1 activation.(A) Flow cytometry analysis was conducted using no less than
100,000 transfected 293 cells per data point. Percentage of cells in each phase was determined by CPX analysis. Graphical representation of the
overall percent of cells from each treatment harboring a DNA content less than G1 (sub-G1) (flow data presented in Additional file 2: Figure
S2A). Error bars reflect SEM between 3 separate transfections. (B-D) Luciferase reporter activity for FOXO1 in cells expressing the indicated
constructs. (B) Errors bars reflect SE. ANOVA with post-hoc Bonferroni correction was performed ** P < 0.01, ***P < 0.001. n = 3. (C-D) Error bars
reflect SE of triplicate transfections within one representative experiment. ***P < 0.001. n = 2.
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Figure 7 Spy1 protein levels are elevated in human breast cancers.(A) TMAs containing cores from invasive ductal carcinoma (IvDC), infiltrated
ductal carcinoma (IfDC), intraductal carcinoma (IDC) and invasive lobular carcinoma (ILC) as well as pair-matched normal (PM-N) or cancer-free
patients (CF-N) were analyzed for Spy1 expression. The Spy1 signal intensity was normalized to nuclear stain (TOTO-3/PI) signal. Patient numbers
are indicated below the sample (N). (B) Breast normal and cancer cell lines were analyzed by western blot analysis. Actin was used as a loading
control. One representative blot of 2. (C) Western blot of 3 replicate infections of pLKO control or pLKO Spy1 in MDA-231 cells. Middle panel
represents the densitometry values over 3 separate experiments. Where Spy1 is corrected for actin levels. Lower panel reflects cell counts at 4, 6,
and 24 h post-infection. (All panels) Data shown is mean ± s.d. Student’s t-test was performed * P < 0.05;**P < 0.01. (D) Knockdown effects on cell
counts of MCF7 cells over 72 h after transfection with either pSUPER empty vector (siCntl) or pSUPER-Spy1 (siSpy1) over 3 separate transfections.
Data shown is mean ± s.d.
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aggressive MDA-231 cell line. Knockdown of Spy1 protein
levels in these lines using lentiviral shRNA significantly
impaired growth of the by 24 h (Figure 7C). It is notable
that although identical numbers of cells were seeded cell
numbers at early time points were also lower with Spy1
knockdown, albeit not statistically significant. Cells
infected with shSpy1 appear to stop growing after 24 h,
hence complicating analysis at later time points but also
supporting that Spy1-mediated activity may play a critical
role in the growth properties of subsets of breast cancer.
To study a longer time course Spy1 was also knocked
down with siRNA previously described [11] using the
slower growing breast cancer line MCF7, expressing sig-
nificantly less Spy1 than the MDA-231 cells (Figure 7D).
Spy1 knockdown significantly impaired growth for up to
72 h post-infection. Our results support the importance of
further examining these effects in vivo. These future
experiments are dependent on developing mechanisms of
more homogeneous and stable Spy1 knockdown.
Conclusions
Collectively, this work supports that critical levels of
Spy1 protein trigger transformation dependent upon the
activation of the G2/M cyclin-dependent kinase, Cdk1.
We further show that this mechanism is sensitive to
inhibition by the apoptotic regulator FOXO1. We have
demonstrated for the first time that levels of Spy1 are
elevated in all human breast cancer samples tested and
that knockdown of Spy1 can reduce breast cancer cell
growth and may represent a novel target for breast can-
cer therapy.
Additional material
Additional file 1: Figure S1 Lysates from Figure 4Dwere IPd with
Cdk1/Cdk2 antibody and subjected to H1 phosphorylation assay
followed by SDS PAGE analysis. One representative experiment of 2.
Additional file 2: Figure S2 (A) Flow profiles from samples
described in Figure 6Aare noted. Transfections are listed above each
profile and the relative% of cells falling within the SubG1 population
noted on each figure. This is one representative experiment of 3, values
noted in 6A are averages over 3 individual experiments. (B)
Representative TMA samples as depicted by microscopy. Spy1 staining is
indicated in green with Alexa-488 secondary. Number on panel indicates
the core number. All images are taken at 10×, scale bars indicate 250
uM.
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